Skip to Content

DaVita Inc

DVA: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$794.00HzbgzPwrzrpvn

DaVita Faces Challenges in Q1 but Maintains its 2022 and Preliminary 2023 Outlook; No FVE Change

Shares of DaVita declined around 6% in after-hours trading after the company reported first-quarter results that were weaker than market expectations. However, given the omicron variant surge during the period and labor challenges permeating the healthcare sector, we weren't terribly surprised with the weak results. Additionally, management maintained its guidance for the full year and noted that treatment volumes even started increasing in March and April.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of DVA so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center